Verastem Inc   (VSTM)
Other Ticker:  
Price: $6.4000 $0.08 1.266%
Day's High: $6.58 Week Perf: -0.47 %
Day's Low: $ 6.30 30 Day Perf: 2.89 %
Volume (M): 44 52 Wk High: $ 13.33
Volume (M$): $ 279 52 Wk Avg: $4.56
Open: $6.32 52 Wk Low: $0.32

 Market Capitalization (Millions $) 171
 Shares Outstanding (Millions) 27
 Employees 73
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -77
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 0

Verastem Inc
Verastem Inc is a biopharmaceutical company that specializes in discovering and developing small molecule drugs to treat cancer. The company is headquartered in Needham, Massachusetts, USA and was founded in 2010. Verastem Inc's focus is on developing medicines that target cancer stem cells, which are thought to be the root cause of tumor growth, recurrence, and metastasis.

The company's lead drug candidate is duvelisib, which is a dual inhibitor of PI3K-delta and PI3K-gamma. These are two enzymes that play a role in cell growth, differentiation, and survival. Duvelisib has been shown to have promising results in clinical trials for the treatment of blood cancers, such as chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and peripheral T-cell lymphoma (PTCL). The drug has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory PTCL and FL.

Apart from duvelisib, Verastem Inc has a pipeline of drug candidates that target cancer stem cells. These include VS-6766, which is a compound that inhibits both MEK and RAF kinases, and VS-6063, which is a focal adhesion kinase (FAK) inhibitor. These drugs are being developed for the treatment of solid tumors, such as ovarian, pancreatic, and lung cancers.

Verastem Inc has collaborations with pharmaceutical companies, academic institutions, and government agencies to advance its drug development programs. The company has a partnership with Yakult Honsha Co., Ltd. for the development and commercialization of duvelisib in Japan. It has also received funding from the National Cancer Institute (NCI) for clinical trials of its drug candidates.

In terms of its financial performance, Verastem Inc reported a net loss of $83 million in 2020. The company has a market capitalization of around $300 million and a share price of around $50 as of August 202 The company has raised over $500 million in funding from investors, including private equity firms, venture capitalists, and institutional investors.

In conclusion, Verastem Inc is a biopharmaceutical company that is focused on developing drugs to target cancer stem cells. Its lead drug candidate, duvelisib, has shown promise in clinical trials for the treatment of certain types of blood cancers. The company has a pipeline of drug candidates for the treatment of solid tumors and collaborations with pharmaceutical companies and research organizations. Despite posting losses in recent years, Verastem Inc remains committed to advancing its research and development efforts to bring innovative treatments to patients with cancer.

   Company Address: 117 Kendrick Street, Suite 500 Needham 2494 MA
   Company Phone Number: 292-4200   Stock Exchange / Ticker: NASDAQ VSTM
   VSTM is expected to report next financial results on March 13, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Evofem Biosciences Inc

Serious revenue fall, at Evofem Biosciences Inc in the fiscal third quarter of 2023

For the third quarter of 2023 Evofem Biosciences Inc had turn a round to earnings by posting EPS of $0.10 per share compare to $-0.04 a year prior and net profit per share turned positive from $-5.43 per share from the preceding financial reporting period. The revenue declined widely by -19.761 % to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior and sequentially Revenue doubled by 107.974 % from $2.46 million.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc. Faces a Bumpy Ride: Operating Results Decline in Recent Fiscal Period for Major Pharmaceutical Preparations Company

In the dynamic and ever-evolving world of the stock market, there are always exciting new opportunities waiting to be discovered. While the major players in the pharmaceutical industry tend to grab most of the headlines, it is often the lesser-known companies that can offer hidden gems for astute investors. One such company, Shuttle Pharmaceuticals Holdings Inc (SHPH), has recently published its financial report for the third quarter of 2023, shedding light on its performance and potential for growth.
Despite reporting an operating loss of $-1.599146 million for the third quarter of 2023, SHPH has displayed a promising upward trajectory. Although the company has not released its top-line figures yet, it is essential to consider its previous accomplishments to put its recent performance into context. In the third quarter of 2022, SHPH recorded an operating loss of $-0.821468 million, indicating significant progress within just one year.

Cingulate Inc

The company declared operating shortfall in the third quarter of 2023

Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.

Harrow Inc

Harrow Inc Achieves Remarkable 49.84% Top-line Surge during Exceptional Q3 2023 Earnings Season

As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.

Renovorx Inc

Renovorx Inc Witnesses Decline in Q3 2023 Financial Performance, Sets Path for Recovery

As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com